Literature DB >> 6177955

Coronary atherosclerosis and plasma lipoproteins: epidemiology and pathophysiologic considerations.

N E Miller.   

Abstract

A variety of epidemiologic, biochemical, and experimental studies have established a direct relationship between low density lipoprotein (LDL) cholesterol concentration and the risk of developing ischemic heart disease. An even stronger inverse relationship has been demonstrated between high density lipoprotein (HDL) cholesterol and the risk of ischemic heart disease (IHD). Both of these associations reflect underlying relationships to atherogenesis. The mechanism by which elevated LDL levels lead to cholesterol ester deposition in arterial smooth muscle cells and/or macrophages is not clear. a causal relationship between low HDL levels and accelerated atherogenesis has not yet been established. Factors which increase plasma LDL concentration or reduce HDL concentration, with a consequent increase in the theoretical risk of coronary atherosclerosis, include obesity, physical inactivity, cigarette smoking, and progestin-containing oral contraceptives. Recent reports have added to this list widely used antihypertensive agents, such as thiazide diuretics and beta-blocking agents. The mechanisms and pathophysiologic significance of such drug-induced changes in lipoprotein levels are not clear. Until more information is available, however, it would seem prudent to avoid, whenever possible, any antihypertensive which in a given patient substantially lowers the HDL/LDL ratio.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6177955

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Evaluation and treatment of hypercholesterolemia--another step.

Authors:  W E May; B L Baker
Journal:  J Gen Intern Med       Date:  1987 Jan-Feb       Impact factor: 5.128

Review 3.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

4.  Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet.

Authors:  M Miyazaki; H Sakonjo; S Takai
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond.

Authors:  Avani A Pendse; Jose M Arbones-Mainar; Lance A Johnson; Michael K Altenburg; Nobuyo Maeda
Journal:  J Lipid Res       Date:  2008-12-05       Impact factor: 5.922

Review 6.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

7.  Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.

Authors:  Sridar V Chittur; Niquiche Sangster-Guity; Paulette J McCormick
Journal:  BMC Genomics       Date:  2008-10-29       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.